[The modern treatment of metastatic castration-resistant prostate cancer].

Abstract

The basic therapy of metastatic prostate carcinoma is androgen deprivation therapy. Unfortunately, almost all patients develop resistance to treatment that leads to castration-resistant prostate cancer. From 2010, 6 new active substances were registered for the treatment of metastatic castration-resistant prostate cancer, which dramatically improved the overall survival of patients. Two of these are treatments for the androgenic axis, the other drugs or therapeutic methods are immunotherapy, chemotherapy, isotope treatment and RANK-ligand inhibition. The year 2018 was a major success in the treatment of nonmetastatic castration-resistant prostate carcinoma, with the FDA authorizing both apalutamide and enzalutamide at this stage. The aim of this review is to present the standard of care of metastatic castration-resistant prostate cancer by disease stage, and to introduce the emerging treatment modalities presently assessed in clinical trials and discuss the open questions.

• Authors: Zsófia Küronya, Krisztina Biró, Anikó Maráz, Lajos Géczi
• Journal: Magyar onkologia (Magy Onkol) Vol. 63 Issue 1 Pg. 41-50 (Mar 19 2019) ISSN: 2060-0399 [Electronic] Hungary
• Vernacular Title: Metasztatikus kasztrációrezisztens prosztatadaganat korszerû kezelése.
• PMID: 30889620 (Publication Type: Journal Article, Review)

Chemical References

• Benzamides
• Nitriles
• Thiohydantoins
• apalutamide
• Phenylthiohydantoin
• enzalutamide

Topics

• Benzamides
• Humans
• Male
• Neoplasm Metastasis (drug therapy, pathology)
• Neoplasm Staging
• Nitriles
• Phenylthiohydantoin (analogs & derivatives, therapeutic use)
• Prostatic Neoplasms, Castration-Resistant (drug therapy, mortality, pathology)
• Thiohydantoins (therapeutic use)